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Abstract 
Background: The Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) has been the largest financial sup-
porter of malaria since 2002. In 2011, the GFATM transitioned to a new funding model (NFM), which prioritizes grants 
to high burden, lower income countries. This shift raises concerns that some low endemic countries, dependent on 
GFATM financing to achieve their malaria elimination goals, would receive less funding under the NFM. This study 
aims to understand the projected increase or decrease in national and regional funding from the GFATM’s NFM to the 
34 malaria-eliminating countries.
Methods: Average annual disbursements under the old funding model were compared to average annual national 
allocations for all eligible 34 malaria-eliminating countries for the period of 2014–2017. Regional grant funding to 
countries that are due to receive additional support was then included in the comparison and analysed. Estimated 
funding ranges for the countries under the NFM were calculated using the proposed national allocation plus the pos-
sible adjustments and additional funding. Finally, the minimum and maximum funding estimates were compared to 
average annual disbursements under the old funding model.
Results: A cumulative 31 % decrease in national financing from the GFATM is expected for the countries included in 
this analysis. Regional grants augment funding for almost half of the eliminating countries, and increase the cumu-
lative percent change in GTFAM funding to 32 %, though proposed activities may not be funded directly through 
national malaria programmes. However, if countries receive the maximum possible funding, 46 % of the countries 
included in this analysis would receive less than they received under the previous funding model.
Conclusions: Many malaria-eliminating countries have projected national declines in funding from the GFATM under 
the NFM. While regional grants enhance funding for eliminating countries, they may not be able to fill country-level 
funding gaps for local commodities and implementation. If the GFATM is able to nuance its allocation methodology 
to mitigate drastic funding declines for malaria investments in low transmission countries, the GFATM can ensure 
previous investments are not lost. By aligning with WHO’s Global Technical Strategy for Malaria and investing in both 
high- and low-endemic countries, the Global Fund can tip the scale on a global health threat and contribute toward 
the goal of eventual malaria eradication.
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Background
Of the approximate 100 countries with endemic malaria, 
34 were defined in 2010 as malaria-eliminating (see 
Table 1), defined here as a country that has a national or 
subnational evidence-based elimination goal and/or is 
actively pursuing elimination (zero malaria transmission) 
within its borders [1]. Among these 34 countries, 78  % 
of financing for malaria programmes has been provided 
Table 1 34 malaria-eliminating countries, national elimination goals (as of 2015), and study inclusion status
Although these 34 malaria-eliminating countries form the basis of this review, the UCSF Global Health Group’s Malaria Elimination Initiative now identifies 35 malaria-
eliminating countries based on progress around the world over the last 5 years [23]
NNEG No National Elimination Goal
a While not eligible for a new allocation under the NFM, Iran has funding through the Global Fund from a previous 5 year grant signed in 2011
b Elimination goal of 2020 declared under the EMMIE regional initiative
Country National elimination goal Eligible for national funding 
in 2014
Eligible for funding 
through a regional initiative
Meets inclusion criteria 
for this analysis?
Eastern Mediterranean and Europe
 Algeria 2015 Not eligible n/a No
 Azerbaijan 2013 Not eligible n/a Yes
 Iran (Islamic Rep.)a 2025 Not eligible n/a Yes
 Kyrgyzstan 2015 Yes n/a Yes
 Saudi Arabia 2015 Not eligible n/a No
 Tajikistan 2015 Yes n/a Yes
 Turkey 2015 Not eligible n/a No
 Uzbekistan 2015 Yes n/a Yes
The Americas
 Argentina NNEG Not eligible n/a No
 Belizeb 2020 Not eligible yes Yes
 Costa Ricab 2020 Not eligible yes Yes
 Dominican Republicb 2020 Not eligible yes Yes
 El Salvadorb 2020 Yes yes Yes
 Mexicob 2020 Not eligible n/a No
 Nicaraguab 2020 Yes yes Yes
 Panamab 2020 Not eligible yes Yes
 Paraguay 2015 Yes n/a Yes
South-East Asia and Western Pacific
 Bhutan 2018 Yes n/a Yes
 China 2020 Not eligible n/a No
 Korea, Dem. Rep. 2025 Yes n/a Yes
 Malaysia 2020 Not eligible n/a No
 Philippines 2030 Yes n/a Yes
 Republic of Korea 2017 Not eligible n/a No
 Solomon Islands 2035 Yes n/a Yes
 Sri Lanka 2014 Yes n/a Yes
 Thailand 2030 Yes yes Yes
 Vanuatu 2025 Yes n/a Yes
 Vietnam 2030 Yes yes Yes
Sub-Saharan Africa
 Botswana 2018 Yes yes Yes
 Cape Verde 2020 Yes n/a Yes
 Namibia 2020 Yes yes Yes
 Sao Tome and Principe 2020 Yes n/a Yes
  South Africa 2018 Not eligible yes Yes
 Swaziland 2015 Yes yes Yes
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by governments themselves [2]; however, the percent-
age of domestic funding can vary widely from country 
to country, ranging from under 10  % in some low- and 
lower–middle-income countries (LMICs) such as the 
Philippines and Tajikistan, and up to 100  % in upper–
middle to high-income countries such Costa Rica, South 
Korea, and Turkey [3].
As the largest international financier to national 
malaria programmes, the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria (GFATM) has played a criti-
cal role in reducing global malaria burden. Between 2000 
and 2011, global financing for malaria increased 18-fold, 
largely due to the creation of the GFATM in 2002 [4]. 
From inception until 2011, the GFATM granted fund-
ing through a “round” system whereby countries would 
submit proposals that were evaluated based on technical 
soundness, alignment with national strategy, and capacity 
for implementation [5]. Under this old funding model, a 
total of US$8.65 billion had been disbursed for malaria, 
93  % of which was spent on high burden countries [2]. 
The remaining 7 % disbursed by the GFATM accounted 
for the largest source of donor assistance for 19 of the 34 
malaria-eliminating countries that received support from 
the GFATM. Although it is a small percentage of the 
overall GFATM malaria portfolio, this amount has cata-
lyzed national progress toward elimination [2], helping to 
reduce malaria cases in the 34 malaria-eliminating coun-
tries collectively by 85 % between 2000 and 2013 [6].
In an effort to become more transparent and system-
atic, the GFATM created the new funding model (NFM) 
in 2012 to increase value for money and focus invest-
ments to hardest hit countries with fewer available finan-
cial resources [7]. With the NFM, the GFATM formalized 
their allocation methodology, largely determined by dis-
ease burden and gross national income (GNI) per capita, 
which emphasized their priority on investments in higher 
burden, lower income countries [8]. Implemented during 
the 2014–2016 funding cycle, the NFM offers a pre-cal-
culated allocation to each country for human immunode-
ficiency virus (HIV), tuberculosis (TB), and malaria.
Under the NFM, countries are first assigned to one of 
four bands based on their disease burden and income 
level (Table  2). Then, the allocation formula is applied 
to determine the country’s national allocation, which 
includes any unspent money left over from grants under 
the old funding model, plus a new allocation amount. 
The malaria disease burden is calculated using the 
number of deaths  +  the number of cases  +  0.5×inci-
dence + 0.5×mortality rate, based on 2000 malaria inci-
dence data (taken from the World Health Organization), 
and country income level defined by GNI per capita [9].
Once the national allocation is determined and pub-
licly announced, countries can develop a concept note for 
submission to the GFATM. During concept note devel-
opment and revisions, the country dialogue process is 
open and countries can make additional modifications to 
the allocation. Such adjustments include changes to the 
disease allocation split between HIV, TB, and malaria or 
other adjustments based on the willingness to pay crite-
ria, defined by the amount the country is willing to invest 
in their own programmes beyond the required counter-
part financing.
The final concept note is then reviewed by the 
GFATM’s Grant Approvals Committee. The commit-
tee can approve eligible countries for additional incen-
tive funding, defined by the GFATM as “a special reserve 
of funding available on a competitive basis awarded to 
applications that demonstrate the greatest potential for 
high impact with additional funds” [10]. Incentive fund-
ing can increase the national allocation up to 15 % and is 
only available to eligible countries in bands 1–3.
Apart from the national allocations, the GFATM 
approved regional grants under the NFM to three regions 
that applied for malaria funding within an amount set 
aside for regional investments. As of January 2016, three 
regional grants have been signed: the Elimination 8 (E8) 
[11] in southern Africa, the Elimination of Malaria in 
Mesoamerica and the Island of Hispaniola (EMMIE) [12] 
and the Regional Artemisinin-resistance Initiative (RAI) 
Table 2 Band assignments for  malaria-eliminating coun-
tries eligible for GFATM national malaria funding
Source: The Global Fund to Fight AIDS, Tuberculosis and Malaria. Overview of the 
Allocation Methodology (2014–2016): The Global Fund’s new funding model .2014 
http://www.theglobalfund.org/documents/fundingmodel/FundingModel_
OverviewAllocation_Methodology_en/. (12 January 2016, date last accessed)
Band 1
Lower income, high burden
Band 2
Higher income, high 
burden
Vietnam Korea, Dem. Rep.
Kyrgyzstan
Nicaragua
Sao Tome and Principe
Solomon islands
Tajikistan
Uzbekistan
Band 3
Lower income, Low burden
Band 4
higher income, low 
burden
 Botswana Bhutan
 Namibia Cape Verde
 Philippines El Salvador
 Swaziland Paraguay
 Thailand Sri Lanka
Vanuatu
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[13] in the Mekong Region. While national grants tend to 
focus on in-country commodities and activities, regional 
grants can play a complementary role, supporting 
activities that may not be funded through country pro-
grammes, such as cross-border surveillance programmes.
Since the GFATM has been such a significant sup-
porter of malaria-eliminating countries, which are by 
definition, low burden and typically middle-income, and 
the financial impact of the NFM’s funding methodology 
is not clear, the authors initiated an analysis to under-
stand the projected increase or decrease national and 
regional funding from the GFATM to the 34 eliminating 
countries.
Methods
Countries included in this analysis
As of 2010, 34 countries have been identified as malaria-
eliminating [1]. Of these, 26 countries were included in 
the analysis; all met at least one of the following criteria: 
recently eligible for a GFATM malaria grant under the 
old funding model; has an active malaria grant from the 
GFATM; is eligible for a malaria grant under the NFM; 
and/or is expected to receive funds from the GFATM 
under a regional malaria grant. The list of countries with 
their stated national elimination goal is given in Table 1. 
Eliminating countries that have never been eligible for 
malaria funding from GFATM or that hold membership 
to the Group of 20 major economies were excluded from 
the analysis (Algeria, Argentina, China, Malaysia, Mex-
ico, Republic of Korea, Saudi Arabia, and Turkey).
Eligibility status of the 34 eliminating countries gener-
ated by the GFATM are shown in Table 1. Nineteen of the 
34 eliminating countries are eligible for NFM national 
malaria funding with allocation amounts ranging from 
US$500,000 to US$27 million. Although 19 countries are 
eligible for national malaria grants and were given alloca-
tions in the NFM, four did not receive an allocation with 
any additional funding apart from the existing, unspent 
funds from previous grants: Kyrgyzstan, Tajikistan, Thai-
land, and Vanuatu. Five countries are not eligible for 
national malaria grants, but are expected to receive funds 
through a regional malaria grant: Belize, Costa Rica, 
Dominican Republic, Panama, and South Africa.
Analysis on national level funding changes
Using publicly available GFATM grant data [14] collated 
in Microsoft Excel 2010, average annual funding from 
the old funding model was calculated using the total dis-
bursed amounts from each country’s most recent active 
malaria grant(s) averaged over the respective grant start 
date through December 31, 2013, the GFATM speci-
fied cut-off date for the round based system. Disbursed 
amounts rather than the signed amounts in grant agree-
ments from the old funding model were used in order to 
avoid “double counting” of money not yet disbursed that 
will later be incorporated into the new NFM national 
allocation. Using the average disbursements from the 
entire previous grant(s), rather than the last 3 years under 
the old funding model, ensures that this analysis com-
pares previous full grants to potential full grants, while 
capturing any programme scale-up or frontloading.
Estimated NFM average annual allocation amounts 
were calculated by averaging the GFATM specified 
national allocation [7] over the 4  year period of 2014–
2017. This time period was used since the next GFATM 
replenishment will take place in the last quarter of 2016. 
Thus, countries will likely not receive new funding until 
mid-2017. No regional grant amounts were included in 
this portion of the analysis.
Average annual grant amounts disbursed under the 
old funding model were compared to average annual 
national allocated amounts under the NFM to determine 
the percent change between old and new average annual 
funding.
A cumulative percent change between the old funding 
model and NFM was calculated between the sum total of 
the old disbursed and new allocated amounts. The cumu-
lative percent change in funding accounts for countries 
that had an unquantifiable percent change (e.g. those that 
received no money under the old funding model, and 
then assigned an allocation under the NFM).
GFATM NFM regional grants
Funding channeled to malaria-eliminating countries 
through the E8, EMMIE, and RAI GFATM regional 
malaria grants was included. While the RAI grant has 
a predetermined country-level breakdown of funding, 
in this analysis country shares for EMMIE and E8 were 
assumed to be divided equally among the countries 
involved and are described in Table 5.
For eliminating countries included in a regional grant, 
the country share of regional grant funding was added 
to the national allocations and a new percent change of 
funding from the previous funding model compared to 
the NFM was calculated.
NFM malaria funding ranges
Since the national malaria allocation is the calculated 
amount a country is eligible for and not necessarily a final 
grant amount, the funding range (minimum and maxi-
mum) each country could receive was estimated, taking 
into account potential adjustments and/or additional 
funding (e.g. regional grant funding under E8, EMMIE, 
and RAI grants) (Table 3). Because regional grants have 
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already been signed, regional funding amounts remain 
constant in this portion of the analysis.
In order to access the full national allocation, each 
country must meet a conditional counterpart financing 
requirement, or a minimum level of government contri-
bution to the national disease programme as a share of 
total government financing plus GFATM financing for 
that disease [9]. The counterpart financing requirement 
is based on a sliding scale of income level: low-income 
countries must reach a minimum threshold contri-
bution of 5  %, lower LMICs must reach a minimum 
threshold contribution of 20  %, upper LMICs must 
reach a minimum threshold contribution of 40  %, and 
upper–middle-income countries must reach a mini-
mum threshold contribution of 60  %. Countries must 
then meet their willingness to pay criteria, which is an 
additional amount beyond the counterpart financing 
requirement. If a country does not meet their willing-
ness to pay criteria, 15 % of the national allocation for 
each disease component can be withheld. Furthermore, 
during the country dialogue process, the country-level 
stakeholder partnership that manages the proposals and 
grants, also known as the Country coordinating mecha-
nism, can adjust the GFATM’s suggested national dis-
ease split, potentially transferring up to 10 % of malaria 
funding to supplement HIV or TB or vice versa. Table 3 
summarizes potential adjustments and additional fund-
ing used to determine the range of a country’s allocation 
from the GFATM.
Percentage adjustments were calculated from the sug-
gested national allocation amounts announced by the 
GFATM in March 2014 [15]. To calculate the minimum 
funding for a country’s malaria programme, the national 
allocations were decreased by 15  % to simulate unmet 
willingness to pay criteria and by an additional 10  % to 
account for a possible Country coordinating mecha-
nism decision to move malaria funding to another dis-
ease. Independent of national allocation adjustments, 
any country’s share of regional grants is consistent in the 
minimum funding amounts.
The maximum potential funding was then calculated 
based on meeting the willingness to pay criteria, a 10 % 
disease split increase, a 15 % increase for incentive fund-
ing (for those in bands 1–3 that are eligible), and addi-
tional regional grant amounts.
NFM minimum and maximum funding amounts compared 
to the old funding model
Both the minimum and maximum funding amounts 
(national allocations plus regional grants) were averaged 
over the 4-year period of 2014–2017 and compared to 
the average annual disbursements under the old funding 
model to determine the range of percent change in fund-
ing for eligible eliminating countries.
Results
Funding changes to the GFATM’s malaria portfolio
Under the NFM, 4.3  % of the GFATM’s malaria portfo-
lio of US$4.5 billion (including national allocations and 
regional malaria grant funding) is allocated to the focus 
countries in this paper (Fig.  1). Of the 4.3, 0.8  % of the 
malaria portfolio supports eliminating countries through 
three regional grants for malaria: E8, EMMIE, and RAI. 
Under the NFM, the total portion of the malaria portfolio 
95.7%
3.5%
0.8%
4.3%
Total: $4.5 billion 
Total allocated to malaria-
controlling countries
Total allocated to  malaria-
eliminang countries
Total allocated to malaria-
eliminang countries through
naonal allocaons
Total amount (signed) to malaria-
eliminang countries through
regional grants
Fig. 1 The GFATM malaria portfolio under the new funding model including national allocations and signed regional malaria grants. The majority 
(95.7 %) of the Global Fund’s portfolio for malaria under the new funding model is allocated to go to countries working to control malaria and 4.3 % 
is allocated to malaria-eliminating countries
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going to malaria-eliminating countries is lower (4.3  %) 
than under the old funding model (7 %).
Analysis on national level funding changes
Changes in annual national funding between the most 
recent grant(s) under the old funding model and the 
average annual allocation under the NFM are shown in 
Table  4. Overall, there is a projected 31  % decrease in 
average annual funding during the 2014–2017 time-
frame for malaria-eliminating countries. Twelve coun-
tries (Azerbaijan, Cape Verde, Dominican Republic, 
Iran, Kyrgyzstan, Philippines, Solomon Islands, Sri 
Lanka, Tajikistan, Thailand, Uzbekistan and Vanuatu) are 
expected to see an extreme decrease (30–100 %) in fund-
ing, with three (Democratic People’s Republic of Korea, 
Swaziland and Vietnam) expected to have a less severe 
Table 4 Average annual disbursements under  the old funding model versus  average annual NFM national allocations 
2014–2017
a  + indicates a percent change was unquantifiable (e.g. a country who had received no previous GFATM funding is allocated funding under the NFM.)
b This is calculated by taking the total grant disbursement through 2013 and dividing it by each grant’s start date through 31-December-2013
c These countries compose the multi-country Western Pacific, whose previous grant was split 60/40 (Solomon Islands:Vanuatu)
Countries Average annual disbursements before the NFM 
as of dec 31st, 2013b
Average annual allocation under NFM: 
2014–2017
Percent changea
Eastern Mediterranean and Europe
 Azerbaijan $1,049,387 $0 −100 %
 Iran $5,461,418 $0 −100 %
 Kyrgyzstan $884,028 $113,074 −87 %
 Tajikistan $2,721,312 $335,802 −88 %
 Uzbekistan $578,319 $350,280 −39 %
Regional subtotal $10,694,464 $799,156 −93 %
The Americas
 Belize $0 $0 0 %
 Costa Rica $0 $0 0 %
 Dominican Republic $1,592,747 $0 −100 %
 El Salvador $0 $963,783 +
 Nicaragua $2,431,682 $2,921,343 20 %
 Panama $0 $0 0 %
 Paraguay $0 $1,338,783 +
Regional subtotal $4,024,429 $5,223,908 30 %
South-East Asia and Western Pacific
 Bhutan $595,598 $641,075 8 %
 Korea, Dem. Rep. $4,878,128 $3,966,350 −19 %
 Philippines $8,594,847 $5,543,637 −36 %
 Solomon Islandsc $2,329,166 $1,617,630 −31 %
 Sri Lanka $5,310,434 $3,194,798 −40 %
 Thailand $13,611,345 $8,914,463 −35 %
 Vanuatuc $1,552,777 $813,042 −48 %
 Vietnam $4,895,794 $3,778,554 −23 %
Regional subtotal $41,768,089 $28,469,547 −32 %
Sub-Saharan Africa
 Botswana $0 $1,282,149 +
 Cape Verde $633,015 $320,537 −49 %
 Namibia $2,431,682 $3,018,565 24 %
 Sao Tome and Principe $1,807,650 $2,733,377 51 %
 South Africa $0 $0 0 %
 Swaziland $1,420,225 $1,290,603 −9 %
Regional subtotal $6,292,571 $8,645,232 37 %
Total $62,779,553 $43,137,843 −31 %
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decrease in funding (1–29  %). Four countries (Bhutan, 
Namibia, Nicaragua, and São Tomé and Príncipe) will see 
increases in funding, ranging between 1 and 54  %. The 
percent change for three countries (Botswana, El Salva-
dor, and Paraguay) could not be quantified, as they have 
not received any prior funding from the GFATM, but 
allocations and potential grants to these countries would 
be an increase. The remaining four countries (Belize, 
Costa Rica, Panama, and South Africa) have no change in 
national funding.
When percent changes for the national allocations 
were aggregated regionally (also shown in Table 4), it is 
clear that the Eastern Mediterranean and Europe and 
the South-East Asia and Western Pacific regions are the 
hardest hit with declines of 93 and 32  %, respectively. 
The majority of the eliminating countries in these regions 
are projected to experience mild to steep declines in 
funding. Malaria-eliminating countries in the Ameri-
cas are expected to see an overall increase of 30 %, while 
malaria-eliminating countries in sub-Saharan Africa will 
likely have an overall 37 % increase in allocations under 
the NFM.
GFATM NFM regional grants
Regional grants provide US$39.6 million over 3  years 
in extra support for 12 malaria-eliminating countries 
located in southern Africa, Central America, and the 
Mekong region (as shown in Table  5) and boost over-
all funding for malaria elimination from −31  % to an 
increase of 32  %. Adding regional grant country shares 
to national funding have a clear positive affect to fund-
ing. With the addition of regional funding, malaria-elim-
inating countries in the Americas are expected to see a 
cumulative 171  % increase in funding compared to the 
old funding model. Similarly, malaria-eliminating coun-
tries in South-East Asia and Western Pacific are expected 
to see an overall 28 % increase in funding, and malaria-
eliminating countries in sub-Saharan Africa are expected 
to see an overall 179 % increase in funding. No regional 
grant funding for malaria has been provided to malaria-
eliminating countries in the Eastern Mediterranean and 
European regions.
NFM malaria funding ranges
As an example, Fig.  2 illustrates the breakdown of the 
estimated funding range available for Vietnam for the 
period of 2014–2017. The range is determined by the 
adjustments made during the country dialogue process 
and the addition of regional grant funding. The area at 
the bottom of the funding range represents Vietnam’s 
portion (US$15 million) of the RAI regional grant. The 
solid fill area represents the full national allocation, which 
totals US$15 million, with the various shaded areas show-
ing the portion of the national allocation Vietnam would 
receive based on unmet willingness to pay criteria and/or 
a reduction of the disease split amount. Possible upward 
adjustments include an increase in disease split funding 
(an additional US$1.51 million) and successful award of 
incentive funding (US$2.27 million) and are represented 
at the top of the funding range. Accordingly, Vietnam’s 
minimum possible funding of about US$26 million would 
include the RAI regional grant share plus the mini-
mum national allocation (unmet willingness to pay and 
a Country Coordinating Mechanism decision to move 
10 % of malaria funding to HIV or TB). Vietnam’s maxi-
mum funding amount of nearly US$34 million includes 
the RAI regional grant share plus the full national alloca-
tion and all upward adjustments (a Country coordinating 
mechanism decision to increase malaria by 10 % and suc-
cessful award of incentive funding).
Applying the same structure, Figs. 3, 4, 5, and 6 show 
the possible funding ranges for eligible eliminating 
Table 5 Regional Grants for malaria under the NFM
The E8 is not structured such that it has country specific breakdowns of funding. For this analysis, it was assumed that the US$17.8 million is divided equally among 
the eight countries (Angola, Botswana, Mozambique, Namibia, South Africa, Swaziland, Zambia and Zimbabwe)
The US$10 million EMMIE regional grant covers ten countries, five of which are eligible for startup funding (Costa Rica, Belize, El Salvador, Mexico, Panama), and 
nine of which are eligible for payouts (all but Mexico). EMMIE is a cash-on-delivery model and of the US$10 million, US$3 million will go to Population Services 
International as the Principal Recipient. Because it will not be known which countries will be successful in meeting targets until the end of years 2 and 3, this analysis 
assumed that the remaining amount (US$7 million) was evenly split over the nine eligible countries and added to startup funding, if applicable
Fifteen percent of the US$100 million RAI regional grant goes to Vietnam and 10 % goes to Thailand
GFATM regional grant for malaria Total grant  
amount
Total estimated to malaria-eliminating 
countries included in grant scope
Malaria-eliminating countries included 
in regional grant scope
Elimination 8 (E8) $17,800,000 $8,900,000 Botswana, Namibia, Swaziland, South 
Africa
Elimination of Malaria in Mesoamerica  
and the Island of Hispaniola (EMMIE)
$10,000,000 $5,666,668 Belize, Costa Rica, Dominican Republic, El 
Salvador, Nicaragua, and Panama
Regional Artemisinin-resistance Initiative 
(RAI)
$100,000,000 $25,000,000 Thailand and Vietnam
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countries for the period of 2014–2017, by region. The 
possible adjustments and additional regional grant fund-
ing have the potential to change the allocations by either 
25 % more or less than the amount originally communi-
cated to the countries in March 2014. In the Americas, 
Belize, Costa Rica, Dominican Republic and Panama 
are not eligible for national grants and thus do not have 
national allocations, however they can receive funding 
through the regional EMMIE award. Similarly, South 
Africa is not eligible for a national allocation, however is 
assumed to receive one-eighth of the E8 regional grant.
NFM minimum and maximum funding amounts compared 
to the old funding model
The range of percent differences between the estimated 
minimum and maximum average annual allocations for 
2014–2017 determined in Figs.  3, 4, 5, 6 are compared 
to average annual disbursements under the old fund-
ing model and are shown in Fig.  7. Percentages on the 
left side of a country’s range indicate the percent change 
between a country’s minimum funding amount com-
pared to their funding under the old funding model. 
Similarly, percentages to the right side of the range indi-
cate the change between a country’s maximum fund-
ing amount compared to funding under the old funding 
model. In the best case scenario (receiving maximum 
funding from the GFATM for malaria), 46 % of the coun-
tries included in this analysis will still see decreases in 
funding (Cape Verde, Philippines, Solomon Islands, Sri 
Lanka, Tajikistan, Thailand, Uzbekistan, and Vanuatu). 
For countries like Bhutan, Namibia, Nicaragua, Sao Tome 
and Principe, Swaziland and Vietnam, the extra adjust-
ments, if made, could mean a considerable increase in 
support for their elimination efforts. Azerbaijan, Domini-
can Republic, Iran, and Kyrgyzstan are no longer eligi-
ble for funding due to either their low malaria burden or 
income level.
Discussion
Under the NFM, a total of US$4.5 billion has been allo-
cated to 75 countries deemed eligible for GFATM malaria 
support through national allocations and countries 
included in three regional grants to E8, EMMIE, and 
RAI [7]. The proportion of the overall GFATM malaria 
portfolio to eligible malaria-eliminating countries has 
decreased—from 7  % under the old funding model to 
4.3  % under the NFM, less than a quarter of which is 
from funding through the three regional grants. Despite 
this small and shrinking portion of GFATM funding, 
this money has been and will continue to be catalytic in 
accelerating toward malaria elimination in these coun-
tries. In contrast, roughly 20  % (US$0.9 billion) of the 
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GFATM malaria portfolio goes to just two countries 
(Democratic Republic of Congo and Nigeria) [7]. Thirty 
percent (US$1.3 billion) goes to ten countries (Burkina 
Faso, Cameroon, Côte d’Ivoire, Ethiopia, Ghana, Kenya, 
Mozambique, Tanzania, Sudan and Uganda) [7].
Currently, there is a projected overall decrease of 31 % 
in allocated national funding to eliminating countries 
from the GFATM. The change in total allocations to the 
eligible eliminating countries compared to previous dis-
bursements under the old funding model varies widely 
by country: some countries are allocated up to 100  % 
more than previous disbursements and other countries 
are allocated significantly less. However, this allocation 
formula provides a preliminary guideline for the signed 
grant amounts, which are shaped by the Country coordi-
nating mechanisms who have the opportunity to negoti-
ate for additional resources based on the country’s needs 
and timelines. This flexibility in the NFM allows for 
countries to take full ownership of the grants once imple-
mented on the ground.
Still, uncertainties remain for countries around the 
grant making process and the adjustments that could 
be applied, including the domestic counterpart financ-
ing requirement and willingness to pay criteria. All 
allocations are conditional on countries reaching their 
minimum counterpart financing requirement, based on 
income level. While 78 % of financing for malaria elimi-
nation is generated at the domestic level, many of the 
low-income and LMICs depend heavily upon GFATM 
financing (such as Bhutan, Nicaragua, Philippines, the 
Solomon Islands, Sri Lanka, and Vietnam) [16] and any 
reduction in donor financing could hinder their efforts 
to eliminate malaria and prevent re-introduction. Past 
estimates calculated from World Malaria Report 2012 
data for years 2005 through 2010 indicate that roughly 
20  % of eliminating countries have not historically met 
what would be a 5–60 % domestic counterpart financing 
requirement [4].
Along with the counterpart financing requirement, 
the willingness to pay adjustment is an effort to increase 
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domestic financing and promote sustainability of 
GFATM investments. While intended to support sus-
tainability, the domestic funding contribution criteria 
require additional facilitation from the GFATM, espe-
cially for countries transitioning to higher income levels. 
The GFATM can help countries advocate for increased 
domestic financing through a variety of channels, using 
tools such as the WHO’s Global Technical Strategy for 
Malaria 2016–2030 [17] and Roll Back Malaria’s Action 
and Investment to Defeat Malaria 2016–2030 [18] to 
demonstrate the strategies and economic investment 
cases for funding, and by leveraging regional organiza-
tions such as the African Leaders Malaria Alliance [19], 
the Asia Pacific Leaders Malaria Alliance [20], and the 
Asia Pacific Malaria Elimination Network [21] to help 
garner the high-level political support and to implement 
tools needed to increase domestic financing.
Analysis of the funding ranges suggests that projected 
funding amounts are quite variable. Countries could 
receive roughly 25  % more or 25  % less than their allo-
cated amounts, as exemplified by the variance in Viet-
nam’s funding range for the period of 2014–2017. If 
Vietnam does not meet the willingness to pay require-
ment and their Country Coordinating Mechanism pri-
oritizes HIV or TB over malaria, their GFATM’s national 
malaria allocation can decrease from about US$15 mil-
lion to just over US$11 million (about 25  % less than 
the full national allocation amount). In this case, the 
minimum funding amount would equal a US$11 mil-
lion national allocation plus US$15 million in regional 
grant funding. Furthermore, if Vietnam’s minimum fund-
ing amount is compared to their average funding under 
the old funding model, they are expected to see a 34  % 
increase in funding. If the Country Coordinating Mecha-
nism prioritizes malaria funding, and the GFATM deter-
mines the country should receive their full incentive 
allocation in addition to their national allocation and 
regional grant funding, it is possible that Vietnam could 
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receive almost US$34 million (about 73  %) more fund-
ing than under the old funding model. However, this is 
not the case for about half of the malaria-eliminating 
countries. Even if they receive their maximum funding 
amount, 46  % of eliminating countries are projected to 
see a decrease in funding from the GFATM under the 
NFM when compared to the old funding model. It is 
unlikely that many countries would receive the estimated 
maximum funding calculated by the post-allocation 
adjustments.
These findings suggest an unpredictable environment 
for malaria programmes to operate in. Due to competing 
disease priorities, some eliminating countries may not 
be able to continue to adequately fund national malaria 
programmes, putting them at higher risk of resurgence. 
Historical evidence suggests that if malaria funds are 
interrupted, programmes are weakened, or interventions 
are disrupted before malaria has been eliminated, there 
is a danger of malaria resurgence [22]. Furthermore, this 
reduction in funding is not limited to malaria-eliminating 
countries; many control countries such as Ethiopia, 
Haiti, Côte d’Ivoire and Uganda are also projected to see 
a decline in funding [7], straining resources in these set-
tings as well. To mitigate the risk of resurgence, account 
for progress in burden reduction, and address the malari-
ogenic potential of endemic countries, the GFATM 
has used malaria epidemiology data from the World 
Health Organization from 2000 to 2010 in the allocation 
methodology.
With the addition of regional grants, a 31  % decrease 
in national funding is augmented to a cumulative 32  % 
increase in funding for malaria-eliminating countries. 
Regional trend analysis suggesst the malaria-eliminat-
ing countries in the Eastern Mediterranean and Europe 
region are expected to see a 93  % decrease in GFATM 
national financing, mainly due to steep declines in 
malaria cases. Malaria-eliminating countries in South-
East Asia and Western Pacific are expected to experience 
an overall 32 % decline in aggregated national funding, as 
countries such as the Philippines, the Solomon Islands, 
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Sri Lanka, and Vanuatu all are expected to experience 
decreases in funding ranging from 30 to 50 %. However, 
with the addition of the RAI regional grant, the elimi-
nating countries in the region are expected to see a 28 % 
increase in funding, mainly through RAI support to Thai-
land and Vietnam. The RAI grant is a particularly strate-
gic investment and is expected to have a positive impact 
for elimination in the region, providing additional sup-
port to higher burden Mekong countries. This is espe-
cially critical given the serious threat of anti-malarial 
drug resistant malaria. Despite the Dominican Republic’s 
recent ineligibility for malaria funding, eliminating coun-
tries in the Americas are expected to see an overall 171 % 
increase with the additional funding through EMMIE, 
particularly to countries that would otherwise be ineligi-
ble for national malaria funding. The malaria-eliminating 
countries in sub-Saharan Africa are expected to see an 
overall 179 % increase in funding due to the addition of 
the E8 grant funds and because Botswana, although pre-
viously eligible, did not receive funding under the old 
funding model but did receive a malaria allocation of 
roughly US$1.3 million under the NFM. The E8 regional 
grant, which will support eight countries in the southern 
Africa region, also includes South Africa, who is other-
wise ineligible for national malaria funding.
Despite providing much needed additional funding 
for elimination, funds granted through regional chan-
nels will likely not fill all the gaps from reduced national 
level allocations as they usually will not cover country 
specific activities or necessary commodity procurement. 
Regional grants can, however, leverage country-level 
efforts by providing complementary investments to sup-
port cross-border initiatives and collaboration that would 
not otherwise be included in country grants. Another 
benefit is that the regional approach is two-pronged; it 
supports both high- and low- transmission countries 
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by creating a platform for data and information sharing 
and provides an opportunity for enhanced collaboration 
between countries.
Because the eliminating countries are a critical part 
of a global movement toward eradication and maintain-
ing essential national level funding is crucial, a mix of 
regional and country investments by the GFATM can lev-
erage the gains already made toward eradicating malaria. 
Country grants support core malaria interventions, while 
regional grants support collaborative surveillance plat-
forms and demonstrate strong value for money by driv-
ing economies of scale among low burden countries. 
The regional grants can also hold regions accountable 
for reaching goals for elimination and eventual global 
eradication by jointly monitoring national and regional 
activities that are mutually reinforcing. Funding from the 
GFATM has been essential to many of the eliminating 
countries, and maintaining this level of funding, through 
a mix of national and regional funding streams, will be 
needed in order protect investments and sustain progress 
toward a malaria-free world.
Limitations
The adjustments made to the national allocation intro-
duce important limitations in this analysis, which affect 
the quantification of the funding ranges for each coun-
try. These ranges were quantified based on the informa-
tion provided by the GFATM; however, other factors 
are evaluated on a case-by-case basis and how decisions 
affect funding is ultimately determined by the GFATM 
and the Country coordinating mechanism. Thus, these 
funding ranges should be taken as estimations to pro-
vide guidance on potential funding ranges from the 
GFATM.
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Another major limitation is the analysis is that due to a sig-
nificant time lag between programme implementation and 
impact on malaria epidemiology, the analysis cannot fully 
assess the financial impact on in-country malaria burden.
There are likely other benefits of the NFM on malaria-
eliminating countries that are outside the scope of this 
analysis. GFATM funding for health system strengthen-
ing, separate from the three disease streams, would likely 
improve overall outcomes across the board.
Conclusion
Funding from the GFATM has been critical for many 
countries to accelerate progress toward malaria elimi-
nation. As the GFATM prioritizes higher burden, lower 
income countries, national funding streams to many 
eliminating countries are projected to be at risk. A 
decrease in national funding could reverse all the hard-
earned gains and returns on the GFATM’s investment 
to-date. For some of these eliminating countries, regional 
grants for malaria have augmented funding for elimina-
tion activities and helped encouraged regional collabo-
ration but they are unable to fill all the gaps in funding 
created through reductions in national funding. Without 
strong national malaria programmes, regional grants may 
be less effective in achieving regional goals. By creating 
a more nuanced allocation formula or a mix of other 
mechanisms to invest in malaria eliminating countries, 
the GFATM has an opportunity to ensure their previ-
ous investments in malaria are not lost. As the global 
community sets its sights on a malaria-free world, the 
GFATM’s continued investments in both high and low-
burden countries will signal alignment with countries 
and regions that are paving the way toward malaria elimi-
nation and eventual eradication.
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